



cancers



an Open Access Journal by MDPI

Targeted Radiation Therapy and Molecular Imaging in Neuroendocrine Cancer

Guest Editor:

Dr. Giovanni Storto

IRCCS-CROB, Referral Cancer
Center of Basilicata, 85028
Rionero in Vulture, Italy

Deadline for manuscript
submissions:

29 November 2024

Message from the Guest Editor

Dear Colleagues,

Neuroendocrine tumors (NETs) represent a group of highly heterogeneous neoplasms that can occur in different organs with an estimated incidence of less than 1/100,000 cases. They generally show an indolent growth rate. Recently, the interest in the use of radioligand therapy (RTL) in the treatment of neuroendocrine tumors has grown, emerging as a therapeutic area in the field of both nuclear medicine and oncology. Diagnostic tools have also improved. RTL has been demonstrated to be well tolerated and economically sustainable, allowing for personalized medicine in the theragnostic era. Although well consolidated studies have already recognized the efficacy of this therapy, there is room to amplify its potentialities in terms of timing and the variety of neoplasms treated.

Dr. Giovanni Storto
Guest Editor



mdpi.com/si/173010

Special Issue



cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI